ORMP — Oramed Pharmaceuticals Inc
NASDAQ · Healthcare · Biotechnology
$5.08
+$0.23 (+4.64%)
Oramed Pharmaceuticals Inc (ORMP) is a biotechnology company listed on NASDAQ. It is led by Nadav Kidron Esq., based in 1185 Avenue of the Americas, New York, NY, United States, 10036. Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.
Latest reported ORMP revenue for 2025-09-30 was $2.0M. Net income was $48.4M. Revenue was up 0.0% from 2025-06-30 to 2025-09-30. ORMP currently screens at market cap $87.2M.
Use this ORMP page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ORMP quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ORMP SEC filings page. Lician reads the product cache first so this HTML stays unique to Oramed Pharmaceuticals Inc even when a live quote feed is slow.
About Oramed Pharmaceuticals Inc
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.
ORMP Key Statistics
Market Cap
$87.22M
Volume
82,585
Previous Close
$4.81
Day Range
$4.74 – $4.86
EPS
-$0.48
Revenue
$0.00
Net Income
-$19.06M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-100.0%
ORMP Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $1.34M | $904.00K | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$19.06M | $5.53M | -$12.26M | -$12.26M |
| EPS (Diluted) | -$0.48 | $0.14 | $0.31 | $0.00 |
Total Assets
$155.28M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$0.00
Operating Cash Flow
-$8.41M
Free Cash Flow
$0.00
Oramed Pharmaceuticals Inc Company Information
- President, CEO & Executive Chairman
- Nadav Kidron Esq.
- Headquarters
- 1185 Avenue of the Americas, New York, NY, United States, 10036
- Website
- www.oramed.com
- Phone
- 844 967 2633
- IPO / Founded
- 2006-04-21
- Sector
- Healthcare
- Industry
- Biotechnology